Walleye Capital LLC Has $731,000 Stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX)

Walleye Capital LLC increased its stake in shares of Prometheus Biosciences, Inc. (NASDAQ:RXDXGet Rating) by 125.9% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 19,364 shares of the biopharmaceutical company’s stock after acquiring an additional 10,792 shares during the period. Walleye Capital LLC’s holdings in Prometheus Biosciences were worth $731,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Nisa Investment Advisors LLC acquired a new position in shares of Prometheus Biosciences during the 1st quarter valued at about $31,000. Rhumbline Advisers increased its holdings in shares of Prometheus Biosciences by 3.4% during the 1st quarter. Rhumbline Advisers now owns 37,177 shares of the biopharmaceutical company’s stock valued at $1,404,000 after acquiring an additional 1,226 shares during the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of Prometheus Biosciences by 10.0% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 14,300 shares of the biopharmaceutical company’s stock valued at $537,000 after acquiring an additional 1,300 shares during the last quarter. Swiss National Bank increased its holdings in shares of Prometheus Biosciences by 7.4% during the 1st quarter. Swiss National Bank now owns 27,600 shares of the biopharmaceutical company’s stock valued at $1,042,000 after acquiring an additional 1,900 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Prometheus Biosciences during the 1st quarter valued at about $86,000. Institutional investors and hedge funds own 74.22% of the company’s stock.

Prometheus Biosciences Price Performance

Shares of RXDX stock opened at $56.58 on Wednesday. The stock has a 50 day moving average of $46.93 and a two-hundred day moving average of $37.22. The company has a current ratio of 13.32, a quick ratio of 13.32 and a debt-to-equity ratio of 0.07. Prometheus Biosciences, Inc. has a 12 month low of $21.50 and a 12 month high of $59.74. The company has a market capitalization of $2.31 billion, a P/E ratio of -17.96 and a beta of 2.30.

Prometheus Biosciences (NASDAQ:RXDXGet Rating) last posted its earnings results on Thursday, August 11th. The biopharmaceutical company reported ($0.86) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.06. The business had revenue of $1.27 million during the quarter, compared to the consensus estimate of $0.70 million. Prometheus Biosciences had a negative return on equity of 54.91% and a negative net margin of 1,700.51%. As a group, equities analysts expect that Prometheus Biosciences, Inc. will post -3.49 EPS for the current year.

Analyst Ratings Changes

RXDX has been the subject of several recent analyst reports. Credit Suisse Group increased their target price on Prometheus Biosciences from $52.00 to $59.00 and gave the company an “outperform” rating in a research note on Friday, August 12th. The Goldman Sachs Group initiated coverage on Prometheus Biosciences in a research note on Wednesday, July 20th. They set a “buy” rating and a $51.00 target price for the company. Wells Fargo & Company increased their target price on Prometheus Biosciences from $51.00 to $71.00 and gave the company an “overweight” rating in a research note on Monday, August 29th. Royal Bank of Canada increased their target price on Prometheus Biosciences from $45.00 to $61.00 in a research note on Friday, August 12th. Finally, SVB Leerink increased their target price on Prometheus Biosciences from $55.00 to $60.00 and gave the company an “outperform” rating in a research note on Friday, August 12th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $60.10.

Prometheus Biosciences Profile

(Get Rating)

Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.

Featured Articles

Institutional Ownership by Quarter for Prometheus Biosciences (NASDAQ:RXDX)

Receive News & Ratings for Prometheus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometheus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.